CALEB FREY: Open Payments
NPI 1245899046 · EVANSVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$905 in 54 payments from 18 companies in 2025. Trend: 2023 $843 · 2024 $941 · 2025 $905
Food & beverage: $905
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $229 |
| Novo Nordisk Inc | 7 | $109 |
| PFIZER INC. | 5 | $94 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $68 |
| GlaxoSmithKline, LLC. | 4 | $63 |
| Corium, LLC | 3 | $60 |
| Viatris Specialty LLC | 2 | $51 |
| Boston Scientific Corporation | 1 | $35 |
| Lilly USA, LLC | 2 | $34 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
Products named: QULIPTA, UBRELVY, Ozempic, NURTEC ODT, CAPLYTA, VRAYLAR, Azstarys, YUPELRI.
Industry payments across IN — which companies pay providers there.
